Therapeutic potential of various β-glucan sources in conjunction with anti-tumor monoclonal antibody in cancer therapy

Driscoll, Michael; Hansen, Richard; Ding, Chuanlin; Cramer, Daniel E.; Yan, Jun · Cancer Biology & Therapy · DOI: 10.4161/cbt.8.3.7337

Research Archive

TL;DR — Key Findings

Yeast glucan outperformed tested mushroom extracts in mouse antibody therapy models.
Dendritic-cell IL-12 and MyD88-related signaling were implicated.
The findings are not clinical or Aureobasidium-specific.

Abstract

Several beta-glucan sources were compared as adjuncts to anti-tumor monoclonal antibodies in mouse tumor models. Yeast beta-glucan produced smaller tumor burdens and longer survival than antibody alone or the tested mushroom extracts, and stimulated stronger IL-12 secretion in dendritic cells. MyD88 contributed to cytokine production. These preclinical comparisons do not establish efficacy in cancer patients and do not directly test Aureobasidium glucan.

Summary

Study

Yeast and mushroom beta-glucans were compared with anti-tumor antibodies in mouse models.

Finding

The tested yeast preparation produced stronger adjuvant effects and IL-12 responses.

Limit

Preclinical results do not establish patient benefit or Aureobasidium equivalence.

AI-generated summary for accessibility. Always refer to the original paper.

Citation

Driscoll, Michael; Hansen, Richard; Ding, Chuanlin; Cramer, Daniel E.; Yan, Jun. Therapeutic potential of various β-glucan sources in conjunction with anti-tumor monoclonal antibody in cancer therapy. Cancer Biology & Therapy. 2009. DOI: 10.4161/cbt.8.3.7337.

Study Details

Study Type

In Vivo

Published

2009

Journal

Cancer Biology & Therapy

Authors

Driscoll, Michael; Hansen, Richard; Ding, Chuanlin; Cramer, Daniel E.; Yan, Jun

DOI

10.4161/cbt.8.3.7337

Access Full Paper

Read Original Paper Access via DOI

Important Notice

For scientific reference only. Not medical advice. Consult a qualified healthcare professional. See our Medical Disclaimer.